Blood pressure in hemodialysis patients is difficult to control. The adequate use of antihypertensive drugs, associated with a good control of blood volume, are the most appropriate measures for the control of blood pressure in these patients. to objective describe the main drug classes used to control hypertension and to describe the epidemiological profile of chronic kidney disease patients on hemodialysis in the city of Cáceres-MT in the year 2014. Descriptive, cross-sectional epidemiological study with patients underwent hemodialysis in 2014 in the city of Cáceres, by means of patient medical records of a total of 17,134 hemodialysis sessions with 133 patients. The majority were male, black, married, with a mean age of 55 years, with hypertensive nephrosclerosis as the underlying disease. The main comorbidity was diabetes mellitus; 80% are diagnosed of end-stage chronic kidney disease; the mean time on hemodialysis (survival) was 4.8 years and 78.6% were hypertensive. Among hypertensive patients, 41.8% used a combination of two antihypertensive drugs and 32.6% used monotherapy; the adrenergic inhibitors class used was 27.1%, and 12.5% received diuretics. There was a mean survival of 5.2 years for hypertensive patients. The drug therapy used to control blood pressure complies with international recommendations in 81.6% of cases. The characteristics of patients being treated are similar to the other cities in the country. The mean survival of the hypertensive group of patients was higher than that of the non-hypertensive group.
INTRODUCTION
Chronic kidney disease (CKD) is defined as renal damage characterized by structural or functional changes in the kidneys with or without a reduced glomerular filtration rate (GFR). Classified in five stages, the last called terminal, the treatment is based on the stage the disease is in. Hemodialysis (HD) is the most used modality for the terminal stage and is considered renal replacement therapy (RRT), with the function of removing toxic nitrogenous substances from the blood and excess water 1 . CKD is a problem of great relevance and is recognized as a complex disease that requires multiple approaches in its treatment. The incidence of CKD increases by around 8% per year. The last Brazilian census of dialysis published in 2016 showed that the number of terminally ill patients was 122,825 with a prevalence rate of 596 patients per million people, and more than 39,714 new patients per year start a RRT 2 . In 2016, the Unified Health System (SUS) SBPsed on 1.8 billion reals for the treatment of RRT patients in HD 3 . Systemic arterial hypertension (SAH) is an increase in blood pressure (BP). SAH is identified as values of systolic blood pressure (SBP) greater than or equal to 140mmHg and/or diastolic blood pressure (DBP) greater than or equal to 90mmHg 1, 4 . SAH is common among hemodialysis patients and can reach between 50 and 90% of the population 2, 5 . Patients on hemodialysis have constant changes in blood pressure, either due to underlying diseases, the evolution of CKD or by the treatment, and unfortunately it is difficult to control. In part, the difficulty in controlling hypertension is related to the variability and complexity involved in BP changes in HD, living conditions, and external factors. The pathophysiology of hypertension in these patients may be related to the progression 159 of CKD or be a complication of HD, and it is still a challenge to recognize the what measures must be taken to achieve BP control 6 . The morbidity and mortality of patients on dialysis have cardiovascular diseases, as their main cause, far outweighing infections, neoplasms and voluntary abandonment of hemodialysis treatment. Cardiovascular mortality in patients undergoing hemodialysis is high, reaching 50% of chronic kidney disease patients; 10 to 20 times higher in comparison with the general population 7 . The influence of SAH on these rates has generated more interest in the study, in the different characteristic aspects of these groups and, apparently, is closely related to nonmodifiable risk factors such as age, sex, race/ color and family history of the disease, as well as modifiable risk factors like environmental conditions (climatic variations), lifestyle, overweight/obesity and poor diets with excess sodium 8 . To know the pharmacological therapy used in the practice of health services and the epidemiological profile of patients on hemodialysis is relevant for the planning of actions, protocols and public policies. This paper aims to describe the main pharmacological classes used to control hypertension and to describe the epidemiological profile of chronic kidney disease patients on hemodialysis in the city of Cáceres-MT in the year 2014.
METHODS
This was a descriptive, cross-sectional epidemiological study with chronic kidney disease patients on hemodialysis in 2014, in the city of Cáceres-MT.
The present study was performed at the Kidney Treatment Center (KTC) in the city of Cáceres-MT. The KTC is a private institution that is part of SUS. The service serves patients with CKD who require renal replacement therapy by hemodialysis, in addition to consultations with nephrologists and general practitioners. The KTC serves the patients of the municipality and of the region, being a reference in this sector for the southwest region of the state of Mato Grosso, encompassing the 22 municipalities.
The city of Cáceres is located in the southwest region of Mato Grosso, with a population of 87,942 inhabitants distributed in a 24,351.44km 2 area. The city of Caceres is watered by the Paraguay River and stands out as the touristic center of the Pantanal Mato Grosso, and also has one of the largest cattle herds in the west-central region of Brazil. It is 118m above sea level, and is 250km from the capital, Cuiabá 9 . Data were collected from the charts of chronic kidney disease patients who underwent dialysis during the period from January to December 2014, and 17,134 hemodialysis sessions were analyzed. The data were collected in a specific form. The following data were collected: date of birth, sex, color/race, marital status, profession, city of residence, date of initiation of hemodialysis, baseline disease, initial diagnosis, blood typing, treatment provider and medications used to treat hypertension. Data were collected from the medical admission form of the patients' medical records, recorded in the first session of hemodialysis.
An initial diagnosis was the diagnosis reported in the medical record that characterized chronic kidney disease in the terminal phase, justifying the patient's entry into hemodialysis; diseases that led the patient to develop end-stage kidney disease were considered to be the baseline diseases, and the other diseases present in medical records that were not reported as underlying diseases were considered comorbidities. The access to the diagnostic and verifying exams was not available for this research. All information was collected as was filled-out in the medical record.
The study included those chronic kidney disease patients over 18 years of age, aged between 21 and 92 years, in a dialysis program for more than three months in January 2014, after signing the informed consent form. One hundred and thirty-three (133) patients who met the inclusion criteria of the study. In 2014, a total of 196 chronic kidney disease patients underwent dialysis. The sample corresponded to approximately 68% of the KTC dialysis patients in 2014. In the present study, patients who underwent dialysis in the year 2014 Medications for hypertension of hemodialysis patients in Cáceres -Mato Grosso, Brazil and used antihypertensive drugs during this period were classified as hypertensive. The use of antihypertensive drugs predicts that the patient's blood pressure is above normal (SBP greater than or equal to 140mmHg and/or DBP greater than or equal to 90mmHg) 4 . Those patients with altered blood pressure in a drugfree therapeutic treatment were not classified as hypertensive. The measurements of arterial pressures in the clinic are performed by the nursing technicians through an indirect method with an auscultatory technique using an aneroid sphygmomanometer at the pre-dialysis, intradialysis and post-dialysis moments.
Antihypertensive 
RESULTS
The male sex was predominant with 60.9% of the individuals; the mean age was 55 years (21-92 years). Regarding the self-reported race/ color, 49.6% declared that they were white; the black representation (brown race added to the black race) corresponded to 50.3%; regarding marital status, 64.6% were married ( Table 1) .
The predominant city of residence was Cáceres, with 52.5% of the patients, and it is where the service is installed. At the time of hemodialysis, 54% reported being retired or at home, and 98.4% were dependent exclusively on SUS to perform the treatment (Table 1) .
Hypertensive nephropathy was the most common baseline disease among participants with 28.5% patients having this diagnosis. The predominant initial diagnosis for hemodialysis was end-stage kidney disease (N180 of the International Code of Diseases-ICD10) ( Table  2) .
Of the 133 medical records surveyed, 45.7% presented arterial hypertension or hypertensive nephropathy as the baseline disease, of which 19.6% were not using antihypertensive medication in 2014 and 90.1% were undergoing drug therapy treatments. Thirtytwo percent of the patients did not present SAH as a baseline disease but used antihypertensive drugs. In total, 73.6% of the participants were classified as hypertensive due to the use of antihypertensive drugs (Table 2) .
Regarding comorbidity, 47.3% of the patients had some disease, and diabetes mellitus was present in 26.3% of them. The hemodialysis time of the participants varied from 1 to 21 years of treatment, with a mean of 4.8 years or 58.7 months ( Table 2 ). The hemodialysis time of hypertensive patients was 5.2 years or 63.3 months.
Of the 98 patients undergoing drug therapy for hypertension, 32.6% used a type of antihypertensive drug, 41.8% combined two antihypertensive drugs, 22.4% used three antihypertensive drugs combined, and 3% used four drugs combined for blood pressure control (Table 3) .
Among the classes of drugs prescribed, angiotensin receptor blockers were the most prescribed as monotherapy (4.8%). Among the combined therapies, the most prescribed class of antihypertensive agents were adrenergic inhibitors (27.1%), followed by calcium blockers (20.1%) and ACE inhibitors (17.3%) in multitherapy prescriptions. Diuretics were used in 12.5% of prescriptions (Table 4) . Of the patients undergoing monotherapy, 53.1% were male, 37.5% presented hypertension as the underlying disease, and 65.6% were between 50 and 69 years old. For those using multitherapy, 57.5% were male, 65.1% had hypertension as the underlying disease, and 48.4% were between 20 and 49 years old. 
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DISCUSSION
The majority of the patients undergoing HD in Cáceres city use the drug therapy regimen with a combination of two or three classes of antihypertensive drugs. The group of adrenergic inhibitors (Methyldopa, Atenolol, Clonidine, Propranolol, Carvedilol) were the most used for the control of hypertension.
In CKD all the different classes of antihypertensive drugs are effective controlling BP, and it is often necessary to associate several antihypertensive drugs. More than 50% of hemodialysis patients use this pharmacological group, with the main classes of antihypertensive drugs prescribed being: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, alpha and beta blockers, diuretics, and vasodilators 1, 10 . In patients undergoing hemodialysis, hypertension is considered when the predialysis mean arterial pressure (MAP) is greater than 106mmHg (~140/90mmHg) with the patient's dry weight (ideal weight of the patient without excess blood volume). Mandatory pharmacological therapy should be initiated in patients with pre-dialysis AP at dry weight when MAP is greater than 106mmHg, or when predialysis MAP with a patient's dry weight is 98 -106mmHg associated with an anemic patient, or with a patient scheduled for erythropoietin, or with a patient who presents left ventricular hypertrophy (LVH). Pharmacological therapy is recommended when the pre-dialysis MAP with dry-weight is 98-106mmHg, associated with the patient on erythropoietin therapy, but is not anemic, does not have LVH, or when pre-dialysis MAP with dry weight is greater 98mmHg associated with the patient with LVH 1 . Regarding the choice of antihypertensive classes for HD patients, the recommendation by the Brazilian Society of Hypertension, Brazilian Society of Nephrology and Cardiology is that the choice be individualized and based on characteristics such as comorbidities, cardioprotective effect of the drug, intra and interdialytic pharmacokinetic characteristics, and side effects 4 . According to Kidney Disease: Improving Global Outcomes 11 , at stage five CKD the BP should be kept below 140/90mmHg. As a nonmedicated measure, dietary salt should be reduced and any medication, except diuretics, may be used in dialysis patients 11 . In this study, eighteen patients still use diuretics, even while undergoing hemodialysis. There is a divergence in the literature regarding the use of diuretics by patients undergoing HD. Although the Brazilian Society of Hypertension, together
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with the Brazilian Society of Nephrology, does not advise against diuretics for these patients, and recommend that loop diuretics be used when the GFR is lower than 30ml/min 4 ; some authors do not report or advise against the use of diuretics for patients undergoing HD 1, 11 . The adrenergic inhibitors were used as a monotherapy in eight participants of the study and were combined with another class in forty-two patients, making this class the most used among the study's participants. Atenolol, a beta-blocker, was given three times a week after dialysis, and effectively controlled hypertension and presented a lower risk of cardiovascular complication compared to Lisonopril 12 . Other authors have shown that beta-blockers improved the survival rate of hemodialysis patients by 16% 13 . In the present study, eight patients used the ACEI class as a monotherapy to control their BP, and twenty-four used ACE inhibitors combined with other drugs. The use of ACE inhibitors reduced the risk of death in 52% of patients who were receiving dialysis and who were using this class of drug, and in 79% of patients treated at 65 years or younger, the absolute risk was reduced by 79% 14 . The association of ACE inhibitors with ARBs is not recommended because, in addition to showing no benefit in cardiovascular outcomes, it added a risk of adverse effects 1, 15 . In the present study, one patient used this combination in a four-drug regimen.
There is little evidence to guide the use of a specific antihypertensive agent, and there are no preferred medications for blood pressure control in patients with stage five chronic kidney disease undergoing HD 1, 4, 16 . A study carried out in Minas Gerais, Brazil, with 177 hypertensive HD patients, the classes of medications most frequently used were diuretics (53.6%), followed by renin-angiotensin system blockers (49.2%), adrenergic inhibitors (46.9%), calcium channel blockers (44.6%), and direct vasodilators (14.2%) 17 . There is a difference in the prescriptions of the drugs verified in this study and in other studies conducted in Brazil, probably due to the lack of consensus in the literature regarding the best drugs to be used. Such prescriptions of antihypertensive drugs seem to follow only the criterion of high-risk cardiovascular diseases presented by kidney patients 4 . It is important to note that diuretic prescribing in Brazil is still very common for HD patients, even with counterindicating reports in the scientific literature 11 . It is emphasized that only the use of antihypertensive drugs cannot control the BP of patients undergoing HD. To achieve this goal, salt restriction and volume control are required. If dialysis does not properly remove excess water and there is no control of sodium intake, hypertension will persist despite the use of antihypertensive medication 1, 4, 11 . The characteristics of gender, race and marital status found in this study are similar to those of studies conducted nationally and internationally 7, 17, 18, 19 . The majority of male patients undergoing HD in the present study agrees with the Brazilian census of dialysis and with other studies carried out in Brazil 4, 7, 19 . A study in Peru and the United States also presented percentages above 55% of male participants 19, 20, 21 . The fact that men are reluctant to seek health care causes many to seek health services with CKD in its terminal phase, which makes them more vulnerable to complications and entry into RRT. The greater frequency of ill men can be explained not only by biological factors, but also by social and psychological factors such as unemployment and stress 19 . The most affected age group is similar to other studies performed nationally, with a mean age ranging from 49 to 53 years 7, 18 . In Pelotas -Rio Grande do Sul, the mean age was 57.9 years, and almost 50% were 60 years or older 18 . North American studies showed a higher average age: over 60 years 20, 21 . From the age of 40, about 0.75 to 1 ml/ min/year of glomerular filtration is lost. If the glomerular filtration rate was verified in an 85-year-old man, the GFR is estimated to be 70ml/min/1.73m² without necessarily representing CKD 1 . With aging, kidney physiology deficiencies can occur with glomerular filtration and tubular function near the threshold of kidney failure susceptibility. The incidence of CKD increases four to eight times in individuals over 70 years of age, Medications for hypertension of hemodialysis patients in Cáceres -Mato Grosso, Brazil denoting the character of CKD as a disease of the elderly, especially in developed countries 21 . The self-reported race of the highest proportion of individuals in this study was the black race followed by the white race. The result of the study did not coincide with the racial characteristics of the resident population in the state of Mato Grosso, in which the majority are brown, followed by white, black, indigenous and yellow races 9 . In the studies carried out in southern Brazil, they found that the majority of the patients stated that they were of the white 19 . On the other hand, in studies from northeastern Brazil, the majority declared to be of a non-white race 7 . The predominance of race varies according to the place of study, mainly in Brazil.
It is difficult to verify the influence of racial factors on kidney disease in Brazil due to miscegenation, and the high degree of racial mixing in Brazil makes it difficult to quantify the influence of race on CKD 22 . There is no conclusive evidence that black and Brazilian ethnic minorities are especially vulnerable to kidney disease, although an US study has shown a greater incidence of the disease among African Americans and points out that CKD is more common in certain ethnic groups 21 . Although black people are more likely to develop CKD, the data show that the population profile of the region influences the percentage of race/color of CKD patients.
Married marital status was the most prevalent, a result similar to other study studies that demonstrated that the majority of subjects in HD were married or lived in stable union with their partners 7, 18 . The marital relationship, as it happens in most of the respondents, has repercussions in home care, because with CKD and hemodialysis, the individual presents various treatment complications as well as the requirement of special care, contributing to functional losses impairing independence and autonomy. The presence of a partner indicates assistance in the care of the person on dialysis.
Most of the patients live in Cáceres, but patients living in neighboring cities depend on public transportation or their own transportation. The distance between the municipalities to Cáceres can vary from 35km to 305km. There are also some patients who live in the rural area of their municipalities, which increases the distance. The same problem was described in João Pessoa -Paraíba with approximately half of the patients being from neighboring cities. These patients traveled far, often remaining all day outside their city of origin, waiting for the other patients who went in the same transport. This displacement probably acts in a negative way, and can be a stressor, which can trigger physiological changes such as increased blood pressure 23 . In this study, the majority of patients were retired when they entered HD, which may be associated with the age group found in the study.
According to Sesso et al. 2 , the SUS is responsible for paying for 83% of the dialyses in Brazil, the percentage found in the study was high which can demonstrate the dependence of patients in this region of Brazil on the SUS.
Most patients had hypertension as their underlying disease, followed by glomerulonephritis. According to the Brazilian Society of Nephrology's 2016 census, hypertension affects 34% of patients with CKD in dialysis, being the main cause of CKD in Brazil, followed by diabetes mellitus (30%) and chronic glomerulonephritis (9%). A study with chronic kidney disease patients in the United States reported that hypertension has a prevalence of 72% in these patients and is associated with 23% of annual mortality 24 . In the northeastern part of Brazil, 70% of the patients undergoing HD had SAH 7 . Regardless of the etiology of CKD, 80% of patients in the terminal stage have SAH when they initiate dialysis, and 40% to 50% of them remain hypertensive even after the onset of RRT 1, 21 . The prevalence of hypertension, determined by the detection of kidney disease, progressively increases as kidney function deteriorates, such that in the terminal or dialytic phase of CKD, almost all nephropathic patients are hypertensive 1 . A relevant proportion of glomerulonephritis was observed, the second cause for underlying diseases in this study. Glomerulonephritis may be associated with infectious agents 1 , these Medications for hypertension of hemodialysis patients in Cáceres -Mato Grosso, Brazil underlying disease characteristics are similar to the profile in an Asian study 5 and diverge from what occurs in more developed countries, where diabetes is the main cause of CKD 21 . Diabetes mellitus as a baseline disease was also found in a study carried out in the Americas 19, 21 . In this study, diabetes was the fourth cause of the underlying disease in patients with this condition.
The initial diagnosis is performed by the physician at the time when the patient initiates hemodialysis and it must justify the reason for the entry into the RRT 1 . In Brazil, the majority of patients on hemodialysis have the diagnosis of end stage chronic kidney disease -N180 (ICD  10) 2 , a result compatible with the research. Diabetes mellitus was the most prevalent comorbidity among the patients participating in the study. Diabetic patients on RRT have lower survival rates than non-diabetics 25 , and the mortality in the first months after the onset of hemodialysis is high among diabetics. In other national studies, diabetes mellitus was also cited as a comorbidity present in patients on HD 8, 19 . The hemodialysis time was the variable that presented little similarity with the other studies. The average time found in this study was 58.7 months, which is above the averages described in other studies ranging from 39.7 to 38.5 months 5, 17 . The average time in hemodialysis of hypertensive patients was 63.3 months, which is longer than the general average in this study and higher than in other studies 5, 17 . A study in southern Brazil found an average time in HD of over 60 months in 28% of the patients 18 . Theoretically, there is no established limit of time undergoing hemodialysis that patients must pass through. It is known that there are many patients with CKD who have had this type of treatment for more than a decade. It is necessary to do a more detailed analysis to relate the factors that may be influencing this average and improving the life span of the patients.
One limitation of the study is that the data recorded in the medical records do not encompass the complete health history of each patient, specifically lacking information about the socioeconomic conditions (income and educational level) to better establish the patient's profile. The lack of access to secondary information such as admission exams and diagnostic tests compromises the verification of the pathologies mentioned in the medical records.
The medications used to treat hypertension in hemodialysis patients in this study were compatible in 81.6% of the cases. We observed that the diuretics class of drugs was still used in this study and is reported in other Brazilian studies, even though this class of drugs is contraindicated for patients undergoing HD by international guidelines. It seems necessary that research must be done to establish adequate drug therapy for these patients.
CONCLUSION
Pharmacological therapy used to control blood pressure complies with international recommendations in 81.6% of cases and is partially divergent from recommendations in the literature with the use of diuretics in 12.5% of patients.
The characteristics of patients being treated are common to other localities in the country. The mean survival of the group of hypertensive patients was higher than that of the nonhypertensive group.
Knowing the social and health profile of patients is important for the elaboration of public policies for the prevention and treatment of chronic kidney diseases. Directing the treatment of hypertension in hemodialysis patients is still a challenge in Brazil and in the world, but the first step is to know the characteristics of the patients and the most used drugs, so that in the future more elaborate studies can demonstrate a more adequate treatment for these patients and for planning actions, protocols and public policies for this group with such specific characteristics. 
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INTRODUÇÃO
A doença renal crônica (DRC) é definida por lesão renal caracterizada por alterações estruturais ou funcionais dos rins com ou sem redução da taxa de filtração glomerular (TFG). Classificada em cinco estágios sendo o último chamado de terminal, o tratamento é baseado no estágio que se encontra a doença. A hemodiálise (HD) é a modalidade mais utilizada para o estágio terminal sendo considerada uma terapia renal substitutiva (TRS), com função de remover substâncias nitrogenadas tóxicas do sangue e excesso de água 1 
RESULTADOS
O sexo masculino foi predominante com 60,9% dos indivíduos; a média de idade foi de 55 anos (21-92 anos). Em relação à raça/ cor autorreferida 49,6% declararam ser da raça branca; a representação negra (raça parda somada à raça preta) correspondeu a 50,3%; quanto ao estado civil 64,6% eram casados (tabela 1).
A cidade de residência predominante foi Cáceres, com 52,5% dos pacientes residindo nesse município, onde está instalado o serviço. Ao ingressar na hemodiálise, 54% relataram ser aposentados ou do lar e 98,4% dependentes exclusivos do SUS para realizar o tratamento (tabela 1).
A nefropatia hipertensiva foi à doença de base mais comum entre os participantes com 28,5% pacientes com esse diagnóstico. O diagnóstico inicial para hemodiálise predominante foi doença renal em estágio final (N180 do Código Internacional de Doenças-CID10) 64,6% pacientes (tabela 2). Dos 133 prontuários pesquisados, 45,7% apresentaram doença de base hipertensão arterial ou nefropatia hipertensiva, dos quais 19,6% não estavam utilizando anti-hipertensivos em 2014 e 90,1% seguiam em tratamento com medicamentos. Trinta e dois por cento dos pacientes não apresentaram HAS como doença de base, mas faziam uso de medicamentos antihipertensivos. No total, 73,6% dos participantes foram classificados com hipertensos por uso de medicamentos anti-hipertensivos (tabela 2).
Em relação a comorbidade 47,3% dos pacientes apresentaram alguma doença, sendo a diabetes mellitus presente em 26,3% deles. O tempo de hemodiálise dos participantes variou de 1 a 21 anos em tratamento, com média de 4,8 anos ou 58,7 meses (tabela 2). O tempo de hemodiálise dos hipertensos foi de 5,2 anos ou 63,3 meses. Dos 98 pacientes em tratamento medicamentoso para hipertensão, 32,6% utilizaram uma classe de antihipertensivo, 41,8% combinação de dois antihipertensivos, 22,4% pacientes utilizaram três Medicamentos para hipertensão de pacientes em hemodiálise em Cáceres -Mato Grosso, Brasil anti-hipertensivos combinados e 3% utilizaram quatro medicamentos combinados para controle da pressão arterial (tabela 3).
Entre as classes de medicamentos prescritos, os bloqueadores dos receptores de angiotensina foi o mais prescrito como monoterapia 4,8%. Entre as terapias combinadas, a classe de anti-hipertensivo mais prescrito foram os inibidores adrenérgicos com 27,1%, seguido dos bloqueadores de cálcio 20,1% e dos IECA com 17,3% nas prescrições de multiterapia. Os diuréticos foram utilizados em 12,5% das prescrições (tabela 4). Dos pacientes em monoterapia, 53,1% eram do sexo masculino, 37,5% apresentaram hipertensão como doença de base e 65,6% tinham entre 50 a 69 anos. Em uso de multiterapia, 57,5% eram do sexo masculino, 65,1% tinham hipertensão como doença de base e 48,4% idade entre 20 a 49 anos. Na DRC todas as diferentes classes de anti-hipertensivos são efetivas no controle da PA, sendo muitas vezes necessário associação de vários anti-hipertensivos. Mais de 50% dos pacientes hemodialisados fazem uso desse grupo farmacológico, sendo as principais classes de anti-hipertensivos prescritos: inibidores da enzima conversora da angiotensina, bloqueadores dos receptores de angiotensina, bloqueadores dos canais de cálcio, alfa e betabloqueadores, diuréticos e vasodilatadores 1, 10 . É considerado hipertensão em pacientes em hemodiálise quando a pressão arterial média (PAM) pré-diálise for maior 106mmHg(~140/90mmHg) com paciente em peso seco (peso ideal do paciente sem excesso de volemia). A terapia farmacológica mandatória deverá ser iniciada ao paciente com PA pré-diálise em peso seco quando PAM for maior 106mmHg ou quando a PAM pré-diálise, com paciente em peso seco, for igual 98 -106mmHg associada a paciente anêmico, a paciente programado para receber eritropoietina ou presença de hipertrofia do ventrículo esquerdo (HVE). A terapia farmacológica é recomendada quando a PAM pré-diálise com paciente em peso seco for igual 98 -106mmHg, associada ao paciente em terapia com eritropoietina, mas não anêmico, sem presença de HVE ou quando a PAM pré-diálise com paciente em peso seco for maior 98mmHg associada ao paciente com HVE 1 17 . Nota-se diferença nas prescrições dos medicamentos verificados nesta pesquisa e em outras realizadas no Brasil, provavelmente em decorrência da não existência de um consenso na literatura a respeito das melhores drogas a serem utilizadas. Tais prescrições de medicamentos anti-hipertensivos parecem seguir apenas o critério de alto risco doenças cardiovasculares apresentadas pelos pacientes renais 4 . Destaca-se o fato da prescrição de diuréticos no Brasil ser ainda muito comum para os pacientes em HD, mesmo com relatos de contraindicações na literatura científica 11 . Ressalta-se que somente o uso de medicamentos anti-hipertensivos não consegue controlar a PA dos pacientes em HD. Para que esse objetivo seja alcançado, são necessários restrição de sal e controle de volume. Se a diálise não remover corretamente o excesso de água e não houver o controle da ingesta de sódio, a hipertensão persistirá apesar do uso da medicação anti-hipertensiva 1,4,11 . As características de sexo, raça e estado civil encontrados neste estudo são semelhantes à dos estudos realizados nacionalmente e internacionalmente 7, 17, 18, 19 . A maioria dos pacientes em HD do sexo masculino do presente estudo condiz com o censo brasileiro de diálise e com estudos realizados no Brasil 4, 7, 19 . Estudo no Peru e Estados Unidos também apresentaram percentuais acima de 55% dos participantes do sexo masculino 19, 20, 21 . O fato de os homens apresentarem certa resistência a procurar assistência à saúde faz com que muitos cheguem aos serviços de saúde com DRC em sua fase terminal, o que os torna mais vulneráveis às complicações e entrada em TRS. A frequência maior de homens doentes pode ser explicada não só por fatores biológicos, mas também por fatores sociais e psicológicos, como desemprego e o estresse 19 . A faixa etária mais acometida assemelhase a outros estudos realizados nacionalmente, com média de idade variando de 49 a 53 anos 7, 18 . Em Pelotas -Rio Grande do Sul, a média de idade foi de 57,9 anos, sendo que quase 50% tinha 60 anos ou mais 18 . Estudos norte-americanos mostraram média de idade mais elevada: maior de 60 anos 20, 21 . A partir dos 40 anos, estima-se uma perda de 0,75 a 1ml/min/ano da filtração glomerular. Se verificada o ritmo de filtração glomerular em um idoso de 85 anos, estima-se a TFG de 70ml/min/1,73m² sem necessariamente representar DRC 1 . Com o envelhecimento podem ocorrer deficiências da fisiologia renal com a filtração glomerular e a função tubular próximas ao limiar de suscetibilidade da falha renal. A incidência da DRC aumenta de quatro a oito vezes em indivíduos com mais de 70 anos, denotando o caráter da DRC como doença do idoso, principalmente em países desenvolvidos 21 . A raça autorreferida de maior proporção de indivíduos nesta pesquisa foi a raça negra seguida da raça branca. O resultado da pesquisa não coincide com a característica de raça da população residente no estado de Mato Grosso que tem a maioria da raça parda, seguida da raça branca, raça negra, indígena e amarela 9 . Nos estudos realizados no sul do Brasil encontraram que as maiorias dos pacientes declaravam ser da raça branca 19 . Por outro lado, em pesquisas no nordeste brasileiro, a maioria declarava ser da raça não branca 7 . As predominâncias de raça são diferentes conforme o local de realização dos estudos, principalmente no Brasil.
Tabela 1 -
É difícil verificar a influência de fatores raciais na doença renal no Brasil devido a miscigenação, sendo o alto grau de mistura de raça no Brasil dificulta quantificar a influência da raça na DRC 22 . Não existem evidências conclusivas de que a raça negra e de minorias étnicas brasileiras sejam especialmente vulneráveis à doença renal, ainda que os estudos nos EUA mostraram incidência maior da doença entre afro-americanos e aponta que a DRC é mais comum em certos grupos Medicamentos para hipertensão de pacientes em hemodiálise em Cáceres -Mato Grosso, Brasil outros estudos nacionais, a diabetes mellitus também foi citada como comorbidade presente em pacientes em HD 8, 19 . O tempo de hemodiálise foi a variável que apresentou pouca semelhança com os demais estudos. A média encontrada nessa pesquisa foi de 58,7 meses, esse tempo está acima das médias descritas em estudos que variam entre 39,7 e 38,5 meses 5, 17 . O tempo médio em hemodiálise dos pacientes hipertensos foi de 63,3 meses, tempo esse maior que a média geral nesta pesquisa e maior que de outras pesquisas 5, 17 . Estudo no sul do Brasil encontrou tempo médio em HD de mais 60 meses em 28% dos pacientes 18 . Teoricamente não está estabelecido um limite de tempo a ser vivido pelos pacientes em tratamento por hemodiálise. Sabe-se que há muitos pacientes com DRC realizando esse tipo de tratamento há mais de uma década. É necessário fazer uma análise mais detalhada para relacionar os fatores que podem estar influenciando essa média e favorecendo o tempo de vida dos pacientes.
Uma limitação do estudo é que os dados registrados nos prontuários não englobam a história de saúde completa de cada paciente, com falta de informações sobre as condições socioeconômicas (renda e grau de instrução) para estabelecer melhor o perfil dos pacientes. A falta de acesso às informações secundárias como exames de admissão e exames diagnósticos compromete a verificação das patologias citadas nos prontuários.
Os medicamentos utilizados para o tratamento da hipertensão dos pacientes em hemodiálise nessa pesquisa foram compatíveis em 81,6% dos casos. Podemos observar que a classe de diuréticos ainda foi utilizada nessa pesquisa e relatada em outras pesquisas brasileiras, mesmo sendo essa classe de medicamentos contraindicada para pacientes em HD em guidelines internacionais. Parece ser necessário que pesquisas sejam realizadas para estabelecer uma terapêutica medicamentosa adequada a esses pacientes.
CONCLUSÃO
A terapêutica farmacológica utilizada para controle da pressão arterial atende a recomendações internacionais em 81,6% dos casos e diverge parcialmente das recomendações da literatura com o uso de diuréticos em 12,5% dos pacientes.
As características dos pacientes em tratamento são comuns a outras localidades do país. A média de sobrevida do grupo de pacientes hipertensos foi maior que do grupo de não hipertensos.
Conhecer o perfil social e de saúde dos pacientes é importante para elaboração de políticas públicas de prevenção e tratamento de doenças renais crônicas. A condução do tratamento da hipertensão nos pacientes em hemodiálise ainda é um desafio no Brasil e no mundo, mas o primeiro passo é conhecer as características dos pacientes e os medicamentos mais utilizados para que no futuro sejam realizados estudos mais elaborados que demonstrem um esquema terapêutico mais adequado para esses pacientes e para o planejamento de ações, protocolos e políticas públicas a esse grupo com características tão específicas.
